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overall SAS score (P  0.001). Baseline to week 4 differ-
ences in overall SAS demonstrate significantly greater im-
provement for nefazodone mono-therapy compared to
CBASP mono-therapy (P  0.032). Conservative esti-
mates of mean direct treatment costs per patient irrespec-
tive of response are $770 (nefazodone), $1800 (CBASP)
and $2500 (combination). Estimated mean direct treat-
ment costs per acute responder are $1700 (nefazodone),
$4000 (CBASP), and $3400 (combination). Multivariate
results are presented that highlight the interrelationships
of treatment modality, disease severity (HAM-D), func-
tional status (SAS, SF-36, and L.I.F.E.) and costs of treat-
ment. CONCLUSIONS: Combination treatment is most
efficacious. Direct treatment cost per acute responder is
lowest for treatments using nefazodone. Further cost-effec-
tiveness results incorporating variation in time-to-response,
other direct costs, and economic benefits associated with
treatment will also be presented.
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OBJECTIVES: Parkinson’s disease is a progressive neu-
rodegenerative disease and important contributor to dis-
ability. We demonstrated health care status, utilization of
health services and total direct costs of Parkinson’s dis-
ease. METHODS: We used a prevalence approach and
aggregate national data sources to determine 1997 US
annual direct medical cost and general health status of
Parkinson’s patients from a societal perspective. A sensi-
tivity analysis varied prevalence and utilization of each
cost factor around a base case. RESULTS: The preva-
lence of idiopathic Parkinson’s disease is 283/100,000
population, of which 82% are greater than 65 years.
Only 3% of the population with Parkinson’s disease re-
port that they are in excellent health, 11% very good,
19% good, 29% fair and 38% in poor health. Total di-
rect costs are $6.6 billion, $3.4 billion for men. Nursing
home costs ($2.9 billion) account for the largest propor-
tion (44%) of these costs, with medications second
($1.95 billion, 29%) and hospitalizations third most
costly ($1.1 billion, 17%). This is about $8,738 per per-
son annually. The elderly carry the greatest cost burden,
highest for the 75–84 year olds ($2.6 billion annually).
Sensitivity analysis showed a maximum variation in cost
from $3.3 to $9.4 billion when varying both utilization
and prevalence estimates. CONCLUSIONS: The societal
cost burden is high considering the low prevalence of the
disease. Other chronic diseases generally cost only $1–
2,000 annually per patient. There is a large self-perceived
health burden, with the majority of patients reporting
“poor” health status. This study demonstrates a high
combined economic and social burden for Parkinson’s
disease patients.
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OBJECTIVE: To assess factors that influence whether
patients with schizophrenia are prescribed second-gener-
ation antipsychotic medications (olanzapine, risperidone)
or traditional antipsychotics. METHODS: Data were ob-
tained from the Schizophrenia Care and Assessment Pro-
gram study. Participant information was collected through
interviews and medical record abstraction (n  294).
Treating physicians were surveyed about their demo-
graphic, professional, and practice characteristics (n 
42). Patient and physician information was linked. Mul-
tivariate logistic regression with patient and physician-
level predictors was estimated. RESULTS: The following
variables were positively associated with second-genera-
tion medication use at P  0.05: a higher baseline
PANSSNS score (e.g. depressed affect), having a physi-
cian who has been in practice less than five years or
greater than 20 years, one who has attended more than
one professional meeting in the last five years, and one
who sees more than 25 patients a week. The following
variables were positively associated with second-genera-
tion medication use at P  0.1 in some of the models: pa-
tient age 35, race other than African-American or White,
diagnosis of other schizophrenia, being uninsured, and
having one or no prior psychotic episodes. Medicare, Med-
icaid, private insurance, CHAMPUS, and other insurance
were not significant predictors. CONCLUSIONS: One of
the perceived advantages of second-generation antipsy-
chotic medications over traditional antipsychotics is their
greater effectiveness at reducing the negative symptoms
of schizophrenia. Consistent with this belief, we find that
physicians are prescribing second-generation antipsy-
chotics to patients who display more negative symptoms.
There is also evidence that physicians may be prescribing
second-generation antipsychotics to younger patients and
those experiencing a first psychotic episode, thus using
second-generation medications as first-line treatments.
We also find that physician characteristics are influencing
whether patients are being prescribed the second-genera-
tion medications. Finally, we do not find evidence that
insurance status influences access to medications.
PMH41
PATTERNS OF ANTIDEPRESSANT USE AND 
CONCOMITANT 
PSYCHOTHERAPEUTIC AGENTS
Fulop G1, Bona JR2, Brookler R1, Nemeroff CB2
1Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA; 
2Emory University, School of Medicine, Atlanta, Georgia, USA
